The human insulin analogue aspart is not the almighty solution for insulin allergy. Although human insulin is beneficial for most diabetic patients, some patients suffer from an allergy to exogenous insulin. Human insulin analogues, lispro... H Takata,Y Kumon,F Osaki,... - 《Diabetes Care》 被...
The absorption of insulin aspart is impaired in lipohypertrophic sitesInsulin-aspart, pharmacokinetics
Admelog® (insulin lispro)SanofiClear20 - 45 minutes45 - 150 minutes3.5 - 4.75 hours Short Acting Regular (Humulin, Actrapid, Velosulin®)Eli Lilly and Novo NordiskClear30 minutes2 - 4 hours5 - 8 hours Intermediate Acting NPH (Insulatard®)Eli Lilly and Novo NordiskCloudy2 - 4 hours...
Avoid long-acting (LA), extended-release (ER), and combination forms of medications, when possible. Shorter-acting medications are eliminated from your body more quickly, and single medications (versus combined drugs in one tablet) give you greater flexibility in dosing. When more than one medi...
Short or rapid-acting insulin analogues allow a better postprandial glucose control and reduce hypoglycaemic risk. Clinical trials with insulin aspart and insulin lispro have demonstrated improved postprandial glucose control in comparison with human insulin, however, studies directly comparing the activities...
A rapid-acting analog insulin may be used to increase the insulin absorption rate in subcutaneous insulin. How long does intravenous insulin last in the body? Intravenous insulin acts rapidly and lasts for a very short duration in the body. To maintain the desired glucose levels in the blood,...
Faster-acting insulin aspart (faster aspart) is insulin aspart (IAsp) in a new formulation, with faster absorption after s.c. injection. Twelve children (mean age 10.4 y), 13 adolescents (mean age 15.1 y) and 15 adults (mean age 20.2 y) received 0.2 U/kg single dose (mean: 8.3 U,...
Preprandial administration of insulin aspart is associated with greater postprandial glucose control than postprandial administrationNA;Inpharma weekly
Human Insulin Analog (Insulin Aspart, IAsp) is Comparable to Human Insulin (HI) in Type 2 DiabetesWe studied the safety and efficacy of IAsp (a fast-acting insulin with a more rapid onset and shorter duration of action than-HI) in a 6-month, multic...
Inpharma Weekly -doi:10.2165/00128413-200012470-00038NoneSpringer International PublishingInpharma Weekly